GAVI Alliance revised vaccine co-financing policy
Co-financing means that countries contribute to the cost of GAVI-supported vaccines by procuring some of the required vaccine doses with non-GAVI funds. The level of required co-financing takes into account a country’s ability to pay and is dependent on its income (GNI) per capita.
What is the purpose of GAVI’s co-financing policy?
The co-financing policy encourages countries to plan for financially sustainable immunisation programmes in preparation for phasing out GAVI support for new vaccines. Recognising that the time frame for attaining financial sustainability varies across countries, the intermediate objective for the world’s poorest countries is enhanced country ownership of vaccine financing.
Immunization financing toolkit Download this resource for policy-makers and program managers, with short briefs on the various options for financing national immunization programs and vaccines. Produced by The World Bank and the GAVI Alliance. |
When is the co-financing policy applied and how does it work?
Since 2007, all countries applying to GAVI for new vaccine support have been required to co-finance a portion of the cost of the requested vaccines -- except for measles 2nd dose vaccines for which no co-financing is required. While countries are not expected to co-finance the requested doses for preventive campaigns with meningococcal A conjugate (Men A) and yellow fever vaccines, they are expected to cover half of the operational expenses for these campaigns.
The co-financing requirements are established on the basis of a country’s income and are calculated on a per dose level. The three country groupings and their related co-financing requirements established under the revised co-financing policy are listed below:
Country Co-financing Groups
Country Group |
GNI per capita threshold |
Co-financing requirement |
Low Income Countries |
GNI per capita below the World Bank low-income threshold |
US$ 0.20 per dose |
Intermediate Countries |
GNI per capita above the World Bank low-income threshold but below the GAVI eligibility threshold |
Starts at US$ 0.20 per dose and increases 15% annually |
Graduating Countries |
GNI per capita above the GAVI eligibility threshold |
Starts at 20% of the projected price of the vaccine (in the year GAVI support ends) and increases linearly over four years to reach the projected price |
When was the co-financing policy approved and when will it be updated?
GAVI has applied a co-financing policy since 2007. GAVI’s revised co-financing policy was approved by the GAVI Board in December 2010 and the new co-financing obligations will take effect in 2012. The policy is scheduled for review and, if required, updating in 2014.
Related downloads
 |
 |
 |